The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

NCT03178123 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Mucosal Melanoma

Interventions

BIOLOGICAL: humanized anti-PD-1 monoclonal antibody Toripalimab
BIOLOGICAL: high-dose recombinant interferon a-2B

Sponsor

Shanghai Junshi Bioscience Co., Ltd.